Celcuity Inc. (NASDAQ:CELC) Receives $29.17 Consensus Price Target from Brokerages

Celcuity Inc. (NASDAQ:CELC) has received a consensus rating of “Buy” from the seven ratings firms that are covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $29.17.

CELC has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Celcuity in a research report on Friday, November 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of Celcuity in a research report on Friday, November 15th. Finally, Stifel Nicolaus boosted their price objective on Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a research report on Monday, October 7th.

Celcuity Price Performance

CELC opened at $10.93 on Tuesday. Celcuity has a 1 year low of $10.35 and a 1 year high of $22.19. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36. The company has a market capitalization of $405.83 million, a price-to-earnings ratio of -4.19 and a beta of 0.74. The firm’s fifty day moving average price is $12.68 and its two-hundred day moving average price is $14.93.

Institutional Trading of Celcuity

A number of large investors have recently bought and sold shares of CELC. nVerses Capital LLC purchased a new position in shares of Celcuity during the 3rd quarter valued at $33,000. Prospera Private Wealth LLC purchased a new stake in Celcuity during the third quarter valued at about $35,000. Values First Advisors Inc. bought a new position in Celcuity during the third quarter worth about $86,000. Quest Partners LLC increased its stake in shares of Celcuity by 31.3% in the second quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock worth $95,000 after purchasing an additional 1,379 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Celcuity in the third quarter valued at approximately $119,000. 63.33% of the stock is owned by hedge funds and other institutional investors.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.